Cerus Corp 1Q 2026: Revenue $59.9M, EPS $(0.01) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.
Cerus Corp reported Q1 2026 results with revenue of $59.9M, a 23% increase year-over-year, and a narrowed net loss of $1.64M compared to $7.72M in Q1 2025. Diluted EPS was $(0.01). Revenue growth was driven by a 24% rise in product sales, particularly in disposable platelet kits. The company is shifting sales strategy towards IFC kits for blood centers. Operational challenges affected gross margins, and inventory was increased to meet demand. Regulatory progress includes advancements in red blood cell system development and contract revenue growth under BARDA agreements.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments